


**SUPPLEMENTAL INFORMATION  
DISCLOSURE CITATION**



Docket No.: RLL-544US

Serial No.: 10/596,059

Applicants: PALLE, *et al.*

Filed: April 16, 2007

Group: 1626

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	S1A1	3,312,590	4/4/1967	Elks, et al.			
	S1A2	3,436,389	4/1/1969	Nathansohn, et al.	C07C	173/10	
	S1A3	3,506,694	4/14/1970	Oxley, et al.	C07C	169/34	
	S1A4	3,639,434	2/1/1972	Oxley, et al.	C07C	169/32	
	S1A5	3,642,896	2/15/1972	Collin, et al.	C07C	85/02	
	S1A6	3,644,353	2/22/1972	Lunts, et al.	C07D	87/40	
	S1A7	3,652,554	3/28/4/1972	Anner, et al.	C07C	169/28	
	S1A8	3,700,681	10/24/1972	Barth	C07D	31/42	
	S1A9	3,705,233	12/5/1972	Lunts, et al.	A61K	27/00	
	S1A10	3,721,687	3/20/1973	Elks, et al.	C07C	160/30	
	S1A11	3,780,177	12/18/197	Ercoli, et al.	A61K	17/00	
	S1A12	3,928,326	12/23/1975	Brattsand, et al.	C07J	17/00	
	S1A13	3,929,768	12/30/1975	Brattsand, et al.	C07J	17/00	
	S1A14	3,937,838	2/10/1976	Wetterlin, et al.	A61K	31/22	
	S1A15	3,947,478	3/30/1976	Woods, et al.	C07J	1/00	
	S1A16	3,980,778	9/14/1976	Ayer, et al.	A61K	31/56	
	S1A17	3,983,233	9/28/1976	Brattsand, et al.	C07J	17/00	
	S1A18	3,992,534	11/16/1976	Brattsand, et al.	C07J	17/00	
	S1A19	3,994,974	11/30/1976	Murakami, et al.	C07C	103/38	
	S1A20	4,011,258	3/8/1977	Wetterlin, et al.	C07C	93/26	
	S1A21	4,014,909	3/29/1977	Torossian, et al.	C07J	31/00	
	S1A22	4,076,708	2/28/1978	Green, et al.	C07J	71/00	
	S1A23	4,081,541	3/28/1978	Bertelli	A61K	31/56	
	S1A24	4,098,803	7/4/1978	Torossian, et al.	C07J	31/00	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SUPPLEMENTAL INFORMATION  
DISCLOSURE CITATION**

Docket No.: RLL-544US

Serial No.: 10/596,059

Applicants: PALLE, *et al.*

Filed: April 16, 2007

Group: 1626

	S1A25	4,115,589	9/19/1978	Lednicer	A01N	9/20	
	S1A26	4,124,707	11/7/1978	Green, et al.	C07J	5/00	
	S1A27	4,158,055	6/12/1979	Sultz, et al.	A61K	31/58	
	S1A28	4,226,862	10/7/1980	Riva, et al.	C07J	5/00	
	S1A29	4,242,334	12/30/1980	Stache, et al.	A61K	31/56	
	S1A30	4,290,962	9/22/1981	Tachi, et al.	C07D	5/00	
	S1A31	4,298,604	11/3/1981	Hammell	A61K	31/56	
	S1A32	4,335,121	6/15/1982	Phillipps, et al.	C07J	7/00	
	S1A33	4,419,364	12/6/1983	Olsson, et al.	A61K	31/27	
	S1A34	4,472,392	9/18/1984	Anderson, et al.	A61K	31/56	
	S1A35	4,472,393	9/18/1984	Shapiro	A61K	31/56	
	S1A36	4,579,985	4/1/1986	Minderhoud, et al.	C07C	1/04	
	S1A37	4,587,236	5/6/1986	Annen, et al.	A61K	31/56	
	S1A38	4,619,921	10/28/1986	Kalvoda, et al.	A61K	31/56	
	S1A39	4,780,469	10/25/1988	Toda, et al.	A61K	31/35	
	S1A40	4,826,868	5/2/1989	Wachter, et al.	A31K	31/415	
	S1A41	4,859,692	8/22/1989	Bernstein, et al.	A61K	31/40	
	S1A42	4,873,259	10/10/1989	Summer, Jr., et al.	A61K	31/38	
	S1A43	4,992,474	2/12/1991	Skidmore, et al.	A61K	31/135	
	S1A44	5,015,746	5/14/1991	Mizushima, et al.	A61K	31/56	
	S1A45	5,126,375	6/30/1992	Skidmore, et al.	A61K	31/135	
	S1A46	5,243,076	9/7/1993	Skidmore, et al.	A61K	31/135	
	S1A47	5,278,156	1/11/1994	Mizushima, et al.	A61K	31/56	
	S1A48	5,482,934	1/9/1996	Calatayud, et al.	A61K	31/58	
	S1A49	5,565,473	10/15/1996	Belley, et al.	A01N	43/42	
	S1A50	5,583,152	12/10/1996	Bernstein, et al.	A61K	31/40	
	S1A51	5,710,170	1/20/1998	Guay, et al.	C07D	213/30	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SUPPLEMENTAL INFORMATION  
DISCLOSURE CITATION**

Docket No.: RLL-544US

Serial No.: 10/596,059

Applicants: PALLE, *et al.*

Filed: April 16, 2007

Group: 1626

	S1A52	5,712,298	1/27/1998	Amschler	C07D	213/75	
	S1A53	5,716,967	2/10/1998	Kleinman	C07D	261/04	
	S1A54	5,837,699	11/17/1998	Sequeira, et al.	A61K	31/56	
	S1A55	5,889,015	3/30/1999	Sequeira, et al.	A61K	31/58	
	S1A56	5,976,573	11/2/1999	Kim	A61K	9/14	
	S1A57	6,057,307	5/2/2000	Sequeira, et al.	A61K	31/56	
	S1A58	6,127,353	10/3/2000	Yuen, et al.	A61K	31/58	
	S1A59	6,180,781	1/30/2001	Yuen, et al.	C07J	17/00	
	S1A60	6,337,324	1/8/2002	Harmenberg, et al.	A61K	31/56	
	S1A61	6,723,713	4/20/2004	Sequeira, et al.	A61K	31/56	
	S1A62	7,183,321	2/27/2007	Li, et al.	A61K	31/155	
	S1A63	2005/0075383	4/7/2005	Palle, et al.	A61K	31/42	
	S1A64	2008/0009533	1/10/2008	Balachandran, et al.	A61K	31/424	
	S1A65	60/598,621	8/4/2004	Palle, et al.			
	S1A66	60/630,517	11/23/200	Palle, et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	S1B1	EP 0 287 436	10/19/1988	EPO	C07D	257/02		NO
	S1B2	EP 0 387 941	9/19/1990	EPO	C07D	413/04		
	S1B3	EP 0 389 359	9/26/1990	EPO	C07D	257/02		NO
	S1B4	EP 0 419 049	12/4/1995	EPO	C07D	401/12		
	S1B5	EP 0 515 684	12/2/1992	EPO	A61K	31/10		
	S1B6	EP 0 542 355	5/19/1993	EPO	C07D	401/12		
	S1B7	EP 0 542 356	5/19/1993	EPO	C07D	401/12		
	S1B8	EP 0 988 292	2/12/2003	EPO	C07D	241/100		
	S1B9	IN 211/DEL/2005	2/2/2005	India				

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE CITATION</b>	Docket No.: RLL-544US	Serial No.: 10/596,059
	Applicants: PALLE, <i>et al.</i>	
	Filed: April 16, 2007	Group: 1626

	S1B10	IN 1098/DEL/2005	5/3/2005	India			
	S1B11	JP 11-071319	3/16/1999	Japan	C07C	47/575	
	S1B12	WO 01/90106	11/29/2001	PCT	C07D	451/00	
	S1B13	WO 02/26723	4/4/2002	PCT	C07D	265/30	
	S1B14	WO 02/32898	4/25/2002	PCT	C07D	451/00	
	S1B15	WO 02/32899	4/25/2002	PCT	C07D	451/10	NO
	S1B16	WO 02/50070	6/27/2002	PCT	C07D	413/14	
	S1B17	WO 2005/021515	3/10/2005	PCT	C07D	261/04	
	S1B18	WO 2005/051931	6/9/2005	PCT	C07D	261/04	
	S1B19	WO 2006/085212	8/17/2006	PCT	C07D	498/10	
	S1B20	WO 2006/090234	8/31/2006	PCT	C07D	261/04	
	S1B21	WO 2006/122770	11/23/2006	PCT	C07D	498/10	NO
	S1B22	WO 2007/045979	4/26/2007	PCT	A61K	31/401	
	S1B23	WO 2007/045980	4/26/2007	PCT	A61K	31/41	
	S1B24	WO 2007/125984	11/8/2007	PCT	C07D	261/04	NO
	S1B25	WO 2008/035316	3/27/2008	PCT			

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	S1C1	Zhang <i>et al.</i> , "Phosphodiesterase-4 as a potential drug target", <i>Expert Opinion on Therapeutic Targets</i> , <u>9</u> (6):1283-1305 (2005)
	S1C2	Houslay <i>et al.</i> , "Keynote Review: Phosphodiesterase-4 as a therapeutic target", <i>Drug Discovery Today</i> , <u>10</u> (22):1503-1519 (2005)
	S1C3	Lambrech <i>et al.</i> , "Pharmacology of Hexahydro-difeniodol Hexahydro-sila-difeniodol and Related Selective Muscarinic Antagonists", <i>Trends in Pharmaceutical Sciences</i> , <u>10</u> , 60-65 (1989)
	S1C4	Birdsall <i>et al.</i> , "Muscarinic Receptor Subclasses", <i>Trends in Pharmaceutical Sciences</i> , <u>4</u> , 459-464 (1983)
	S1C5	Coruzzi, <i>et al.</i> , "Gastric Antisecretory Activity of Telenzepine, A New M <sub>1</sub> - Selective Muscarinic Antagonist: Comparison with Pirenzepine", <i>Arch Int Pharmacodyn Ther</i> , <u>302</u> , 232 - 241 (1989)
	S1C6	Kawashima <i>et al.</i> , "Pharmacological Differentiation of Presynaptic M <sub>1</sub> Muscarinic Receptors Modulating Acetylcholine Release from Postsynaptic Muscarinic Receptors in guinea-Pig Ileum", <i>Gen. Pharma.</i> , <u>21</u> (1), 17-21 (1990)
	S1C7	Burnouf <i>et al.</i> , "Synthesis, Structure-Activity Relationships, and Pharmacological Profile of 9-Amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1- <i>h</i> ]indoles: Discovery of Potent, Selective Phosphodiesterase Type 4 Inhibitors", <i>Journal of Medicinal Chemistry</i> , <u>43</u> (25):4850-4867 (2000)

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<b>SUPPLEMENTAL INFORMATION DISCLOSURE CITATION</b>	Docket No.: RLL-544US	Serial No.: 10/596,059
	Applicants: PALLE, <i>et al.</i>	
	Filed: April 16, 2007	Group: 1626

S1C8	Tian <i>et al.</i> , "1,3-Dipolar Cycloaddition Reactions of Nitrile Oxides to Prop-1-ene-1,3-sultone" <i>Journal of Heterocyclic Chemistry</i> , <u>40</u> (6):1071-1074 (2003)
S1C9	Salgado-Zamora <i>et al.</i> , "Oxidative degradation of arylfuro-1,2-oxazoles to aryl nitriles by potassium permanganate" <i>Heterocyclic Communications House</i> , <u>7</u> (3):209-212 (2001)
S1C10	Hassikou <i>et al.</i> , "Synthèse de nouveaux polyhétérocycles" <i>Tetrahedron Letters</i> , <u>42</u> (34):5857-5861 (2001)
S1C11	Syassi <i>et al.</i> , "Nouvelle méthode de synthèse des 4,5-dihydroisoxazoles en milieu biphasique solide-liquide et par activation ultrasonique" <i>Tetrahedron Letters</i> , <u>40</u> (40), 7250-7209 (1999)
S1C12	Subramanian <i>et al.</i> , "Facile Synthesis of 3-Aroyl-3-Sulfolenes Through Cycloadditions of Arylnitrile Oxides & 3-Sulfolene" <i>Synthetic Communications</i> , <u>27</u> (15):2557-2562 (1997)
S1C13	Brahmeshwari <i>et al.</i> , "Synthesis of 3-arylnaphth[2,3- <i>d</i> ]-isoxazole-4, 9-diones from Lawsone", <i>Indian Journal of Chemistry, Section B</i> , <u>34B</u> (2):139-140 (1995) - <b>ABSTRACT ONLY</b>
S1C14	Gaboury and Sibi, "Enantiocontrolled Synthesis of Burseran, Brassilignan, Dehydroxycubebin, and Other Tetrahydrofuran Lignans in Both Enantiomeric Forms. Application of Intermolecular Nitrile Oxide Cycloadditions and Lipase Mediated Kinetic Resolutions" <i>Journal of Organic Chemistry</i> , <u>58</u> (8):2173-2180 (1993)
S1C15	Brahmeshwari <i>et al.</i> , "Synthesis and Biological Activity of Fused Heterocycles Derived From Embelin" <i>Indian Journal of Chemistry, Section B</i> , <u>30B</u> (3):369-370 (1991) ) - <b>ABSTRACT ONLY</b>
S1C16	Awad and Sobhy, "1,3-Dipolar Cycloaddition of Nitrile Oxides. II. Reactions with o-quinoid Structures" <i>Canadian Journal of Chemistry</i> , <u>47</u> (9):1473-1477 (1969)
S1C17	Syassi <i>et al.</i> , "Addition Dipolaire-1,3 des Arylnitriloxides avec quelques Dipolarophiles Oléfiniques sur Alumine en Milieu sec et sous Micro-ondes", <i>Tetrahedron Letters</i> , <u>38</u> (51):8855-8858 (1997)
S1C18	Descacq <i>et al.</i> , "Arylpyrazolines nitrofuraniques: synthèse et propriétés antibactériennes", <i>European Journal of Medicinal Chemistry</i> , <u>25</u> (3):285-290 (1990)
S1C19	Bisagni <i>et al.</i> , "Synthesis of 3-aryl-4-acetyl-1H-pyrazolo[3,4- <i>b</i> ]pyridines and 3-aryl-4-acetyl-1H-pyrazolo[4,3- <i>c</i> ]pyridines" <i>Heterocycles</i> , <u>29</u> (9):1815-1824 (1989)
S1C20	Haiza, "Synthesis of some new 3,5-bisaryl-2-pyrazoline derivatives of expected antimicrobial activities", <i>Al-Azhar Bulletin of Science</i> , <u>8</u> (2):445-454 (1997) - <b>ABSTRACT ONLY</b>
S1C21	Varache-Beranger <i>et al.</i> , "Thienylbenzofurans and Arylthienylpyrazolines: Synthesis and Inhibitory Effects on Platelet Aggregation in vitro", <i>Bulletin de la Societe de Pharmacie de Bordeaux</i> , <u>127</u> (1-2-3-4):37-48 (1988) - <b>Abstract only</b>
S1C22	Vanden Eynde and Mailleux, "Quaternary Ammonium Salt-Assisted Organic Reactions in Water: Alkylation of Phenols", <i>Synthetic Communications</i> , <u>31</u> (1):1-7, (2001)
S1C23	Guay <i>et al.</i> , "Discovery of L-791,943: A Potent, Selective, Non Emetic and Orally Active Phosphodiesterase-4 Inhibitor", <i>Bioorganic and Medicinal Chemistry Letters</i> , <u>12</u> (11):1457-1461 (2002)
S1C24	Chauret <i>et al.</i> , "Improving Metabolic Stability of Phosphodiesterase-4 Inhibitors Containing a Substituted Catechol: Prevention of Reactive Intermediate Formation and Covalent Binding", <i>Bioorganic and Medicinal Chemistry Letters</i> , <u>12</u> (16):2149-2152 (2002)
S1C25	Langlois, "Improvement of the Synthesis of Aryl Difluoromethyl Ethers and Thioethers by Using a Solid-Liquid Phase-Transfer Technique", <i>Journal of Fluorine Chemistry</i> , <u>41</u> (2):247-261 (1988)
S1C26	Raju <i>et al.</i> , "Conformationally Restricted Analogs of Deoxynegamycin", <i>Bioorganic and Medicinal Chemistry Letters</i> , <u>14</u> (12):3103-3107 (2004)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>SUPPLEMENTAL INFORMATION DISCLOSURE CITATION</b>	Docket No.: RLL-544US	Serial No.: 10/596,059
	Applicants: PALLE, <i>et al.</i>	
	Filed: April 16, 2007	Group: 1626

	S1C27	Vinick <i>et al.</i> , "An Efficient Synthesis of 1-Phenyl-1-Piperidino-trans-4-Methylcyclohexane: Unanticipated Total Stereoselectivity in the Catalytic Hydrogenation of an Olefin", <i>Tetrahedron Letters</i> , <u>28</u> (7):741-744 (1987)
	S1C28	King <i>et al.</i> , "(±) 3-Amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole: A Conformationally Restricted Analogue of 5-Carboxamidotryptamine with Selectivity for the Serotonin 5-HT <sub>1D</sub> Receptor", <i>Journal of Medicinal Chemistry</i> , <u>36</u> (13):1918-1919 (1993)
	S1C29	Noguchi <i>et al.</i> , "Total Synthesis and Absolute Configuration of Radiosumin, a Strong Trypsin Inhibitor From the Blue-green Alga <i>Plectonema Radiosum</i> ", <i>Heterocycles</i> , <u>58</u> :471-504 (2002)
	S1C30	Shang <i>et al.</i> , "Diastereoselective Cycloadditions of a Soluble Polymer-supported Substituted Allyl Alcohol Derived From Baylis-Hillman Reaction with Nitrile Oxides", <i>Tetrahedron</i> , <u>64</u> (24):5779-5783 (2008) – <b>ABSTRACT ONLY</b>
	S1C31	Walters <i>et al.</i> , "The Preparation of 5-Aryl-5-methyl-4,5-dihydroisoxazoles From Dilithiated C(α),O-oximes and Select Acetyl Ketones", <i>Synthetic Communications</i> , <u>33</u> (23):4163-4171 (2003)
	S1C32	Vippagunta <i>et al.</i> , "Crystalline solids", <i>Advanced Drug Delivery Reviews</i> , <u>48</u> :3-26 (2000)
	S1C33	Chawla and Bansal, "Challenges in Polymorphism of Pharmaceuticals", <i>CRIPS</i> , <u>5</u> (1):9-12 (2004)
	S1C34	Newman and Byrn, "Solid-state Analysis of the Active Pharmaceutical Ingredient in Drug Products", <i>Drug Discovery Today</i> , <u>8</u> (19):898-905 (2003)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	